MA55219A - Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral - Google Patents

Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral

Info

Publication number
MA55219A
MA55219A MA055219A MA55219A MA55219A MA 55219 A MA55219 A MA 55219A MA 055219 A MA055219 A MA 055219A MA 55219 A MA55219 A MA 55219A MA 55219 A MA55219 A MA 55219A
Authority
MA
Morocco
Prior art keywords
capsid
free
viral dna
lipid nanoparticles
active lipid
Prior art date
Application number
MA055219A
Other languages
English (en)
Inventor
Matthew Manganiello
Matthew G Stanton
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MA55219A publication Critical patent/MA55219A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055219A 2019-03-06 2020-03-06 Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral MA55219A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814460P 2019-03-06 2019-03-06
US201962857557P 2019-06-05 2019-06-05

Publications (1)

Publication Number Publication Date
MA55219A true MA55219A (fr) 2022-01-12

Family

ID=72337571

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055219A MA55219A (fr) 2019-03-06 2020-03-06 Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral

Country Status (8)

Country Link
US (1) US20220175968A1 (fr)
EP (1) EP3934700A4 (fr)
AU (1) AU2020232790A1 (fr)
CA (1) CA3131130A1 (fr)
IL (1) IL286026A (fr)
MA (1) MA55219A (fr)
SG (1) SG11202109426YA (fr)
WO (1) WO2020181168A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108728491B (zh) * 2018-06-21 2022-08-26 陕西杆粒生物科技有限公司 一种广谱抗凋亡杆状病毒表达载体
IL299925A (en) 2020-07-27 2023-03-01 Anjarium Biosciences Ag Compounds of DNA molecules, methods for their preparation and methods of using them
EP4267253A1 (fr) * 2020-12-23 2023-11-01 Spark Therapeutics, Inc. Procédés pour améliorer la thérapie génique non virale
WO2022240806A1 (fr) * 2021-05-11 2022-11-17 Modernatx, Inc. Administration non virale d'adn pour expression prolongée de polypeptide in vivo
AU2022288618A1 (en) * 2021-06-07 2023-12-14 Generation Bio Co. Apoe and apob modified lipid nanoparticle compositions and uses thereof
WO2024079531A2 (fr) * 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Éléments régulateurs d'acide nucléique pour l'expression génique dans le foie et procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006561A1 (fr) * 2004-07-12 2006-01-19 Japan Science And Technology Agency Construction d'acides nucleiques
AU2009234266B2 (en) * 2008-04-11 2015-08-06 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP3689381A1 (fr) * 2010-06-22 2020-08-05 Onxeo Système d'administration in vivo optimisé doté d'agents endosomolytiques pour conjugués d'acides nucléiques
CA2989157A1 (fr) * 2015-06-11 2016-12-15 University Of Miami Traitement et diagnostic du cancer
JP6994140B2 (ja) * 2016-03-03 2022-02-03 ユニバーシティ オブ マサチューセッツ 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖dna

Also Published As

Publication number Publication date
CA3131130A1 (fr) 2020-09-10
WO2020181168A1 (fr) 2020-09-10
US20220175968A1 (en) 2022-06-09
SG11202109426YA (en) 2021-09-29
IL286026A (en) 2021-10-31
EP3934700A4 (fr) 2022-12-14
AU2020232790A1 (en) 2021-09-16
EP3934700A1 (fr) 2022-01-12
WO2020181168A8 (fr) 2020-10-01

Similar Documents

Publication Publication Date Title
MA55219A (fr) Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral
IL272799A (en) Lipid nanoparticle formulations of non-viral capsid-free DNA vectors
MA52709A (fr) Administration d'adn
MA40924A (fr) Cathéter avec ensembles d'électrodes empilés
JP2018529501A5 (fr)
DK3911354T3 (da) AVV-formidlet genterapi, der genskaber otoferlin-genet
ITUB20152212A1 (it) Telaio ripiegabile per passeggini, carrozzine e simili.
GB201603296D0 (en) Chemotactic,drug-containing polymersomes
Sherwood et al. Are we wired differently?
Alefantis et al. Sanofi Pasteur
Sinha et al. Targeted ExSeq--Tissue Preparation
Wallis The So-Called Right to Try
Boruch DRAWINGS
ഡോ. ലിസ്സി മാത്യു വി. പത്രാധിപക്കുറിപ്പ്
Gaffney 13 Sawn-off Tales
李玉峰 Sonoco Product
JP2016222625A5 (fr)
庞鑫 et al. How to Choose a Major
UA40374S (uk) Тачка будівельна
UA40375S (uk) Тачка будівельна
*** Marty's Birthday Gift
Andrä et al. Zu den Autoren
Diaz Eaton Have you heard about QUBES?
CL2020000451S1 (es) Cápsula.
郭铃 Récit à la voix de MARGUERITEDURAS